Researchers have found Brukinsa to be a potentially safer alternative for patients with chronic lymphocytic leukemia.

In a Community Case Forum in partnership with the North Carolina Oncology Association, Cristina Gasparetto, MD, discussed the ...

For some patients with bladder cancer, neoadjuvant chemotherapy plus bladder-saving concurrent chemoradiation therapy was ...

FDA convened a joint meeting of its Drug Safety and Risk Management Advisory Committee and the Psychopharmacologic Drugs ...

During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first ...

For patients with previously untreated chronic lymphocytic leukemia (CLL), fixed-duration acalabrutinib-venetoclax wit ...

Tremtelectogene empogeditemcel (trem-cel) may make gemtuzumab ozogamicin maintenance safer for patients with high-risk acute myeloid leukemia (AML), according to results of a phase 1/2 trial presented ...

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...

With clozapine, other problems seem to be overshadowed by the possibility of neutropenia. These include serious conditions such as pneumonia, seizures, myocardiopathy, and constipation. Ileus is ...

X4 has entered an exclusive agreement with taiba rare for distributing and commercialising Xolremdi in select Middle Eastern ...

Obinutuzumab B-cell depleting therapy is more effective than standard care in treating patients with active proliferative lupus nephritis.

Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health, provides new insights on the role of TROP2-directed antibody drug conjugates (ADCs) for patients with breast cancer.